{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T14:01:58Z","timestamp":1780236118092,"version":"3.54.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,31]]},"DOI":"10.7759\/cureus.109966","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T13:34:52Z","timestamp":1780234492000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Safety of Next-Generation Antibody-Drug Conjugates in HER2-Low and Triple-Negative Breast Cancer: A Narrative Review (2020-2025)"],"prefix":"10.7759","author":[{"given":"Rutvik","family":"Raval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankalp","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamitha","family":"Hejmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhay","family":"Prakashkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya L","family":"Kansara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elmoursy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi S","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al.. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022, 387:9-20. 10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini F","year":"2021","unstructured":"Schettini F, Chic N, Bras\u00f3-Maristany F, et al.. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021, 7:1. 10.1038\/s41523-020-00208-2","journal-title":"NPJ Breast Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1378010","article-title":"Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database","volume":"15","author":"Long P","year":"2024","unstructured":"Long P, Li S, Pan L, Wang Y, Chen W, Wang X. Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database. Front Pharmacol. 2024, 15:1378010. 10.3389\/fphar.2024.1378010","journal-title":"Front Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino P","year":"2020","unstructured":"Tarantino P, Hamilton E, Tolaney SM, et al.. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020, 38:1951-62. 10.1200\/JCO.19.02488","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain SM","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003, 97:2869-79. 10.1002\/cncr.11407","journal-title":"Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale D","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, et al.. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015, 131:1981-8. 10.1161\/CIRCULATIONAHA.114.013777","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.40336","article-title":"Cardiotoxic effects of antibody drug conjugates vs standard chemotherapy in ERBB2-positive advanced breast cancer: a systematic review and meta-analysis","volume":"8","author":"Seth L","year":"2025","unstructured":"Seth L, Bhave A, Kollapaneni S, et al.. Cardiotoxic effects of antibody drug conjugates vs standard chemotherapy in ERBB2-positive advanced breast cancer: a systematic review and meta-analysis. JAMA Netw Open. 2025, 8:e2540336. 10.1001\/jamanetworkopen.2025.40336","journal-title":"JAMA Netw Open"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia A","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, et al.. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021, 384:1529-41. 10.1056\/NEJMoa2028485","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia A","year":"2025","unstructured":"Bardia A, Jhaveri K, Im SA, et al.. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol. 2025, 43:285-96. 10.1200\/JCO.24.00920","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA\u2014a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref11","unstructured":"U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Database. (2024). https.\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-adverse-event-reporting-system-faers-database."},{"key":"ref12","unstructured":"European Society for Medical Oncology (ESMO). (2025). Accessed. May 7, 2026: https:\/\/www.esmo.org\/."},{"key":"ref13","unstructured":"American Society of Clinical Oncology (ASCO). (2025). Accessed. May 7, 2026: https:\/\/www.asco.org\/."},{"key":"ref14","unstructured":"San Antonio Breast Cancer Symposium (SABCS). (2025). https.\/\/www.sabcs.org\/."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman A","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, et al.. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002, 20:1215-21. 10.1200\/JCO.2002.20.5.1215","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone SA","year":"2002","unstructured":"Crone SA, Zhao YY, Fan L, et al.. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002, 8:459-65. 10.1038\/nm0502-459","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06280-x","article-title":"Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies","volume":"188","author":"Dempsey N","year":"2021","unstructured":"Dempsey N, Rosenthal A, Dabas N, Kropotova Y, Lippman M, Bishopric NH. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat. 2021, 188:21-36. 10.1007\/s10549-021-06280-x","journal-title":"Breast Cancer Res Treat"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05191-2","article-title":"Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study","volume":"175","author":"Lynce F","year":"2019","unstructured":"Lynce F, Barac A, Geng X, et al.. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019, 175:595-603. 10.1007\/s10549-019-05191-2","journal-title":"Breast Cancer Res Treat"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma S","year":"2012","unstructured":"Verma S, Miles D, Gianni L, et al.. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012, 367:1783-91. 10.1056\/NEJMoa1209124","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani Y","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, et al.. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016, 22:5097-108. 10.1158\/1078-0432.CCR-15-2822","journal-title":"Clin Cancer Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada T","year":"2019","unstructured":"Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019, 67:173-85. 10.1248\/cpb.c18-00744","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani Y","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016, 107:1039-46. 10.1111\/cas.12966","journal-title":"Cancer Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-050311-201823","article-title":"Antibody-drug conjugates in cancer therapy","volume":"64","author":"Sievers EL","year":"2013","unstructured":"Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013, 64:15-29. 10.1146\/annurev-med-050311-201823","journal-title":"Annu Rev Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen TD","year":"2023","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers (Basel). 2023, 15:713. 10.3390\/cancers15030713","journal-title":"Cancers (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12050953","article-title":"Safety profile of the trastuzumab-based ADCs: analysis of real-world data registered in EudraVigilance","volume":"12","author":"Morgovan C","year":"2024","unstructured":"Morgovan C, Dobrea CM, Butuca A, et al.. Safety profile of the trastuzumab-based ADCs: analysis of real-world data registered in EudraVigilance. Biomedicines. 2024, 12:953. 10.3390\/biomedicines12050953","journal-title":"Biomedicines"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2291","article-title":"Exposure-response relationships in patients with HER2-positive metastatic breast cancer and other solid tumors treated with trastuzumab deruxtecan","volume":"110","author":"Yin O","year":"2021","unstructured":"Yin O, Iwata H, Lin CC, et al.. Exposure-response relationships in patients with HER2-positive metastatic breast cancer and other solid tumors treated with trastuzumab deruxtecan. Clin Pharmacol Ther. 2021, 110:986-96. 10.1002\/cpt.2291","journal-title":"Clin Pharmacol Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg DM","year":"2015","unstructured":"Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015, 6:22496-512. 10.18632\/oncotarget.4318","journal-title":"Oncotarget"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid P","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al.. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020, 382:810-21. 10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo HS","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, et al.. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023, 402:1423-33. 10.1016\/S0140-6736(23)01245-X","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review","volume":"63","author":"Thavendiranathan P","year":"2014","unstructured":"Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014, 63:2751-68. 10.1016\/j.jacc.2014.01.073","journal-title":"J Am Coll Cardiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana JC","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, et al.. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014, 15:1063-93. 10.1093\/ehjci\/jeu192","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf170","article-title":"Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy","volume":"13","author":"Cardinale D","year":"2002","unstructured":"Cardinale D, Sandri MT, Martinoni A, et al.. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002, 13:710-5. 10.1093\/annonc\/mdf170","journal-title":"Ann Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01779","article-title":"Cardiac dysfunction among breast cancer survivors: role of cardiotoxic therapy and cardiovascular risk factors","volume":"43","author":"Bostany G","year":"2025","unstructured":"Bostany G, Chen Y, Francisco L, et al.. Cardiac dysfunction among breast cancer survivors: role of cardiotoxic therapy and cardiovascular risk factors. J Clin Oncol. 2025, 43:32-45. 10.1200\/JCO.23.01779","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck N","year":"2026","unstructured":"Harbeck N, Modi S, Pusztai L, et al.. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Ann Oncol. 2026, 37:166-79. 10.1016\/j.annonc.2025.10.019","journal-title":"Ann Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.02.015","article-title":"Trastuzumab deruxtecan in hormone receptor-positive, HER2-low\/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4\/6 inhibitor and baseline burden of disease","volume":"37","author":"Curigliano G","year":"2026","unstructured":"Curigliano G, Hu X, Dent R, et al.. Trastuzumab deruxtecan in hormone receptor-positive, HER2-low\/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4\/6 inhibitor and baseline burden of disease. Ann Oncol. 2026, 37:849-60. 10.1016\/j.annonc.2026.02.015","journal-title":"Ann Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"Cort\u00e9s J","year":"2025","unstructured":"Cort\u00e9s J, Punie K, Barrios C, et al.. Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. N Engl J Med. 2025, 393:1912-25. 10.1056\/NEJMoa2511734","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)","volume":"43","author":"Lyon AR","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al.. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022, 43:4229-361. 10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann J","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S, et al.. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022, 43:280-99. 10.1093\/eurheartj\/ehab674","journal-title":"Eur Heart J"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian SH","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, et al.. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017, 35:893-911. 10.1200\/JCO.2016.70.5400","journal-title":"J Clin Oncol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1641618","article-title":"Nanotechnology-driven synergy in cardio-oncology: enhancing tumor suppression and reducing cardiotoxicity","volume":"16","author":"Ma L","year":"2025","unstructured":"Ma L, Zhang B, Liu X, et al.. Nanotechnology-driven synergy in cardio-oncology: enhancing tumor suppression and reducing cardiotoxicity. Front Pharmacol. 2025, 16:1641618. 10.3389\/fphar.2025.1641618","journal-title":"Front Pharmacol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2016.02.078","article-title":"Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy","volume":"32","author":"Virani SA","year":"2016","unstructured":"Virani SA, Dent S, Brezden-Masley C, et al.. Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol. 2016, 32:831-41. 10.1016\/j.cjca.2016.02.078","journal-title":"Can J Cardiol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky B","year":"2014","unstructured":"Ky B, Putt M, Sawaya H, et al.. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014, 63:809-16. 10.1016\/j.jacc.2013.10.061","journal-title":"J Am Coll Cardiol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s11936-018-0641-z","article-title":"Role of biomarkers in prediction of cardiotoxicity during cancer treatment","volume":"20","author":"Tan LL","year":"2018","unstructured":"Tan LL, Lyon AR. Role of biomarkers in prediction of cardiotoxicity during cancer treatment. Curr Treat Options Cardiovasc Med. 2018, 20:55. 10.1007\/s11936-018-0641-z","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello V","year":"2021","unstructured":"Quagliariello V, De Laurentiis M, Rea D, et al.. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. 2021, 20:150. 10.1186\/s12933-021-01346-y","journal-title":"Cardiovasc Diabetol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy","volume":"77","author":"Thavendiranathan P","year":"2021","unstructured":"Thavendiranathan P, Negishi T, Somerset E, et al.. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol. 2021, 77:392-401. 10.1016\/j.jacc.2020.11.020","journal-title":"J Am Coll Cardiol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2011.11.022","article-title":"Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis","volume":"5","author":"Lurz P","year":"2012","unstructured":"Lurz P, Eitel I, Adam J, et al.. Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. JACC Cardiovasc Imaging. 2012, 5:513-24. 10.1016\/j.jcmg.2011.11.022","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1957","article-title":"Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)","volume":"22","author":"\u010celutkien\u0117 J","year":"2020","unstructured":"\u010celutkien\u0117 J, Pudil R, L\u00f3pez-Fern\u00e1ndez T, et al.. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020, 22:1504-24. 10.1002\/ejhf.1957","journal-title":"Eur J Heart Fail"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano JL","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, et al.. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016, 37:2768-801. 10.1093\/eurheartj\/ehw211","journal-title":"Eur Heart J"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.06.007","article-title":"Past, present, and future of radiation-induced cardiotoxicity: refinements in targeting, surveillance, and risk stratification","volume":"3","author":"Bergom C","year":"2021","unstructured":"Bergom C, Bradley JA, Ng AK, Samson P, Robinson C, Lopez-Mattei J, Mitchell JD. Past, present, and future of radiation-induced cardiotoxicity: refinements in targeting, surveillance, and risk stratification. JACC CardioOncol. 2021, 3:343-59. 10.1016\/j.jaccao.2021.06.007","journal-title":"JACC CardioOncol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano G","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, et al.. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020, 31:171-90. 10.1016\/j.annonc.2019.10.023","journal-title":"Ann Oncol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati G","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, et al.. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016, 37:1671-80. 10.1093\/eurheartj\/ehw022","journal-title":"Eur Heart J"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-00923-w","article-title":"Cardioprotective strategies to prevent cancer treatment-related cardiovascular toxicity: a review","volume":"22","author":"Upshaw JN","year":"2020","unstructured":"Upshaw JN. Cardioprotective strategies to prevent cancer treatment-related cardiovascular toxicity: a review. Curr Oncol Rep. 2020, 22:72. 10.1007\/s11912-020-00923-w","journal-title":"Curr Oncol Rep"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1161\/RES.0000000000000473","article-title":"Preclinical models of cancer therapy-associated cardiovascular toxicity: a scientific statement from the American Heart Association","volume":"129","author":"Asnani A","year":"2021","unstructured":"Asnani A, Moslehi JJ, Adhikari BB, et al.. Preclinical models of cancer therapy-associated cardiovascular toxicity: a scientific statement from the American Heart Association. Circ Res. 2021, 129:e21-34. 10.1161\/RES.0000000000000473","journal-title":"Circ Res"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-025-10531-0","article-title":"Cancer therapy-induced cardiotoxicity: mechanisms and mitigations","volume":"30","author":"Shil S","year":"2025","unstructured":"Shil S, Kumar P, Mumbrekar KD. Cancer therapy-induced cardiotoxicity: mechanisms and mitigations. Heart Fail Rev. 2025, 30:1075-92. 10.1007\/s10741-025-10531-0","journal-title":"Heart Fail Rev"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30050-X","article-title":"The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study","volume":"6","author":"Mulrooney DA","year":"2019","unstructured":"Mulrooney DA, Hyun G, Ness KK, et al.. The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study. Lancet Haematol. 2019, 6:e306-16. 10.1016\/S2352-3026(19)30050-X","journal-title":"Lancet Haematol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.08.045","article-title":"A novel two-dimensional echocardiographic image analysis system using artificial intelligence-learned pattern recognition for rapid automated ejection fraction","volume":"49","author":"Cannesson M","year":"2007","unstructured":"Cannesson M, Tanabe M, Suffoletto MS, McNamara DM, Madan S, Lacomis JM, Gorcsan J 3rd. A novel two-dimensional echocardiographic image analysis system using artificial intelligence-learned pattern recognition for rapid automated ejection fraction. J Am Coll Cardiol. 2007, 49:217-26. 10.1016\/j.jacc.2006.08.045","journal-title":"J Am Coll Cardiol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcac070","article-title":"European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment","volume":"9","author":"Lee GA","year":"2022","unstructured":"Lee GA, Aktaa S, Baker E, et al.. European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment. Eur Heart J Qual Care Clin Outcomes. 2022, 9:1-7. 10.1093\/ehjqcco\/qcac070","journal-title":"Eur Heart J Qual Care Clin Outcomes"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/491745-cardiovascular-safety-of-next-generation-antibody-drug-conjugates-in-her2-low-and-triple-negative-breast-cancer-a-narrative-review-2020-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T13:34:54Z","timestamp":1780234494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/491745-cardiovascular-safety-of-next-generation-antibody-drug-conjugates-in-her2-low-and-triple-negative-breast-cancer-a-narrative-review-2020-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":57,"URL":"https:\/\/doi.org\/10.7759\/cureus.109966","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,31]]}}}